Previous close | 12.48 |
Open | 12.80 |
Bid | 10.55 |
Ask | 13.00 |
Strike | 2.50 |
Expiry date | 2026-01-16 |
Day's range | 12.80 - 12.80 |
Contract range | N/A |
Volume | |
Open interest | 607 |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.